The establishment of the Scientific Department in cooperation with Heinrich Wieland in 1917 and cooperations with Pfizer, Novo and Geigy around 1950 with the aim of building up an international business, are just two important historic examples of partnerships. Partnerships will continue to play a significant role in future efforts to offer customers measurable, affordable therapeutic progress beyond purely innovative medicines. Only when the most innovative companies act together can we find solutions – and at the same time remain an independent, family-owned company.
Partnering helps us to strengthen our capabilities and serve our customers better. Partners allow us to improve our ability to innovate, our ability to compete and to look beyond our own horizon. Partnering is decisive in building strong relations with our customers, better understanding their needs and allowing them to improve their results, hence bringing more health to patients.
In our Animal Health business partnerships have become vital for success in many key dimensions: we supply additional services to our customers in order to provide value beyond the product. Regarding R&D, we work together with several external partners to develop innovative technologies and research approaches. Many ideas for products and solutions are only possible in diverse teams combining different skills and capabilities worldwide. Building global hubs for intensified cooperation is therefore part of our Animal Health strategy that will be vastly accelerated through the integration of Merial.
I see partnerships as central to the future success of Boehringer Ingelheim. For me, partnerships require, firstly, having an in-depth understanding of our customers’ needs and then meeting these needs in a mutually beneficial way. Future partnerships are likely to include cooperating with payers and reimbursement bodies to define the value of our products to society, and being paid on the delivery of this value. Partnerships will also involve gaining expertise from outside the company and employing this to be more competitive and responsive.
Partnership means supporting each other by sharing knowledge and combining strengths. In the Finance Division this does not apply only to our external partners, but to our internal business partners in particular. Together with them, we can overcome the challenges of major projects and thereby achieve optimised results.
Partnerships are key to the success of our company. When I think about partnerships I think about partnerships both internally as well as externally, at all levels within and outside of our organisation. I think about partnerships with our customers, patients, stakeholders and our employees. If we work together, collaborate and foster an inclusive culture we will drive diverse thinking and innovation in our organisation. In a true partnership you are a team, striving for the same goal. TEAM is another way of saying “Together Everyone Achieves More”.
Partnerships are the key to innovation. Discoveries are not made by individuals acting on their own. They usually begin with a single person’s idea that is tested experimentally and, in discussions and exchange with other creative minds both internally and externally, is further developed into a true solution. Our aspiration at Boehringer Ingelheim is to be the partner of choice for external innovators. Establishing a creative and cooperative environment, bringing together scientists from diverse backgrounds, is the key to our ambition for breakthrough innovation valued by patients, their families and society.